PMID- 37934677
OWN - NLM
STAT- MEDLINE
DCOM- 20240108
LR  - 20240108
IS  - 1746-6318 (Electronic)
IS  - 1746-630X (Linking)
VI  - 19
IP  - 1
DP  - 2024 Jan 1
TI  - Clinical consequences of weight gain during treatment for HIV infection.
PG  - 21-29
LID - 10.1097/COH.0000000000000829 [doi]
AB  - PURPOSE OF REVIEW: The introduction of dolutegravir, an oral integrase inhibitor, 
      within public health HIV programs has been a success, with excellent sustained 
      viral load suppression, persistence, and safety. Initial concerns around 
      integrase-inhibitors being implicated in safety concerns around immune 
      reconstitution inflammatory syndromes (IRIS), neural tube defects, and weight 
      gain, have been largely laid to rest, but new concerns about cardiovascular risk 
      have arisen, including a link between hypertension and this antiretroviral class. 
      RECENT FINDINGS: We review the pertinent studies here, and while we find both 
      observational and randomized controlled study associations in some but not all 
      studies, these are often confounded by associated weight gain and aging. In 
      addition, definitions of hypertension, as well as measurement within the studies 
      (such as cuff size), were not consistent within studies. SUMMARY: Careful 
      analysis will be needed, as with the weight-gain signal, before assigning 
      causation, especially as plausible physiological mechanisms for this rise in 
      blood pressure are unclear.
CI  - Copyright (c) 2023 Wolters Kluwer Health, Inc. All rights reserved.
FAU - Hill, Andrew
AU  - Hill A
AD  - Department of Pharmacology and Therapeutics, University of Liverpool, Liverpool, 
      UK.
FAU - Venter, Willem Daniel Francois
AU  - Venter WDF
AD  - Wits Ezintsha, Faculty of Health Sciences, University of the Witwatersrand, 
      Johannesburg, South Africa.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20231106
PL  - United States
TA  - Curr Opin HIV AIDS
JT  - Current opinion in HIV and AIDS
JID - 101264945
RN  - 0 (Heterocyclic Compounds, 3-Ring)
RN  - 0 (HIV Integrase Inhibitors)
RN  - 0 (Pyridones)
SB  - IM
MH  - Humans
MH  - Heterocyclic Compounds, 3-Ring/adverse effects
MH  - *HIV Infections/drug therapy
MH  - *HIV Integrase Inhibitors/adverse effects
MH  - Hypertension/drug therapy
MH  - Pyridones/adverse effects
MH  - Weight Gain
EDAT- 2023/11/07 18:42
MHDA- 2023/12/17 09:45
CRDT- 2023/11/07 12:53
PHST- 2023/12/17 09:45 [medline]
PHST- 2023/11/07 18:42 [pubmed]
PHST- 2023/11/07 12:53 [entrez]
AID - 01222929-990000000-00073 [pii]
AID - 10.1097/COH.0000000000000829 [doi]
PST - ppublish
SO  - Curr Opin HIV AIDS. 2024 Jan 1;19(1):21-29. doi: 10.1097/COH.0000000000000829. 
      Epub 2023 Nov 6.